Stella Xu is the Managing Director of Quan Capital, a life sciences venture fund with offices in China and the US. See sector focus and contact routes.
Stella Xu is the Managing Director of Quan Capital, a life sciences venture fund with offices in China and the US, where she joined in January 2017 after serving as VP and Site Head of Roche Innovation Center Shanghai. Her investment thesis targets early- and growth-stage life sciences companies globally, with a focus on China, covering therapeutic biotech, enabling technologies, precision medicine, oncology, immunology, and rare diseases. Quan Capital invests across pre-seed, seed, Series A, and Series B stages, though specific check sizes and whether Xu leads or follows deals are not publicly disclosed. Notable portfolio companies where she serves on the board include Therorna Inc., Zidan Medical, and HBM Healthcare Investment, and she previously held board roles at Armo BioSciences, Centrexion Therapeutics, Design Therapeutics, NextCure, and Tempest Therapeutics. Xu holds a Ph.D. in Immunology from Northwestern University and a B.S. in Biophysics from Peking University, and her background includes core R&D leadership at Roche’s Immunology, Inflammation & Infectious Diseases areas. No distinctive public writing or unique point of view from Xu is docum
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Shanghai.
Investors like Stella Xu · Full investor directory · Investor access · Company funding database